Leuven will give healthy people an inflammation, then a memory test

A triple-blind trial at UZ Leuven randomises colon-release short-chain fatty acid capsules against placebo, then injects every volunteer with bacterial endotoxin and measures what happens to working memory, inhibition and task switching. It is a cause test in a field built mostly on correlations.

In a research room at University Hospital Leuven, a healthy volunteer swallows a capsule built to stay shut until it reaches the colon. Later, a measured dose of bacterial endotoxin goes into a vein. Then comes the part that should interest anyone who has watched a parent lose the thread of a sentence: a test of working memory, taken while the immune system is in uproar.

The study is registered as NCT07713641, sponsored by Universitaire Ziekenhuizen KU Leuven under the protocol number S69844. Its official title is plain about the design: a randomized, triple-blind, placebo-controlled trial investigating short-chain fatty acids in endotoxemia-induced inflammation and core executive functioning. It began recruiting on 24 October 2025, was verified by the sponsor in June 2026, first posted on 20 July 2026, and is estimated to complete on 30 March 2027. One site, Leuven, Belgium. Status: recruiting.

The arithmetic of the challenge is in the registration. Every participant receives a single intravenous bolus of lipopolysaccharide at 0.4 nanograms per kilogram of body weight, a fixed inflammatory condition applied to both arms. The randomisation sits elsewhere, in a two-arm parallel comparison of short-chain fatty acid colon-delivery capsules against placebo. The syringe carries the provocation. The thing under test arrives by mouth and is timed to open where the bacteria live.

Short-chain fatty acids are what your gut bacteria make for a living. Acetate, propionate and butyrate, all three named in the trial's own keyword list, are the end products of fibre fermentation in the large intestine. They are the most ordinary molecules in the body and among the most argued over.

Here is why the design matters more than another survey of stool samples. Most of what gets published about gut bacteria and the brain is observational: count the microbes in people who already have a diagnosis, find a pattern, publish the pattern. Those studies cannot tell you which came first. This one assigns the metabolite by lot, provokes the inflammation on a clock, and keeps participants, staff and assessors blind to who got what.

The Leuven group has run the rehearsal. In 2020, Boushra Dalile, Kristin Verbeke, Lukas Van Oudenhove and colleagues reported in Neuropsychopharmacology that colon-delivered short-chain fatty acids attenuated the cortisol response to psychosocial stress in healthy men, in a randomized placebo-controlled trial. All three are listed as principal investigators on the new study. They have already shown the molecules reaching the stress axis. Now they are aiming at the immune axis, and at the cognitive functions that sit downstream of it.

The registration names its territory in its keywords: working memory, cognitive inhibition, response inhibition, cognitive flexibility, task switching, sickness behaviour. Those are the capacities a family actually notices going. Holding a phone number in your head while you find a pen. Stopping a sentence you have started. Changing plan when the pharmacy is closed.

Anyone who has had a real fever knows the feeling from the inside. The thinking goes thick, the word you want stays one shelf out of reach, and it lifts when the temperature does. This trial puts a small, controlled version of that state into healthy adults and asks whether a gut metabolite changes its shape.

What it is not doing is studying dementia. The registration lists its primary purpose as basic science, its phase as not applicable, and its participants as healthy volunteers. Nobody in this trial has a diagnosis, nothing here is a treatment, and there are no results to read: primary completion is estimated for 30 March 2027, and the sponsor has marked individual data sharing undecided.

For the daughter reading this between a work call and a pharmacy run, the useful part is the method, not the hope. If short-chain fatty acids blunt the cognitive cost of an immune hit in people with nothing wrong with them, the gut-to-brain story stops being a correlation and starts being a link you could test in people who need it. If they do nothing, that is worth knowing too, and it will be known by spring 2027 at the earliest.

A capsule that opens in the colon, a vial that goes into a vein, and a screen asking you to remember four letters in order. Small apparatus, serious question: whether the bacteria in your gut have a vote on how clearly you think when your body is fighting something.